What is the current valuation of the market as of 2024?

The market was valued at 2.022 USD Billion in 2024. Read More

What is the projected market valuation for the market in 2035?

The market is projected to reach 3.362 USD Billion by 2035. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 4.73%. Read More

Which companies are considered key players in the market?

Key players in the market include GSK, Merck & Co., Sanofi, AbbVie, Bharat Biotech, Serum Institute of India, China National Pharmaceutical Group, and Zydus Cadila. Read More

How does the market segment for Monovalent and Combination vaccines compare in terms of valuation?

In 2024, the Monovalent segment was valued at 1.212 USD Billion, while the Combination segment was valued at 0.81 USD Billion. Read More

What are the projected valuations for the Pediatric, Adult, and Geriatric age groups in the Hepatitis B Vaccine Market?

The Pediatric segment is expected to grow from 0.606 USD Billion to 0.978 USD Billion, the Adult segment from 0.606 USD Billion to 1.078 USD Billion, and the Geriatric segment from 0.81 USD Billion to 1.306 USD Billion. Read More

What distribution channels are utilized in the Hepatitis B Vaccine Market, and what are their valuations?

Distribution channels include Hospital Pharmacies valued at 0.606 USD Billion, Retail Pharmacies at 0.404 USD Billion, Clinics at 0.606 USD Billion, and Online Portals at 0.406 USD Billion in 2024. Read More

What is the expected growth trajectory for the Combination vaccine segment by 2035?

The Combination vaccine segment is projected to grow from 0.81 USD Billion in 2024 to 1.384 USD Billion by 2035. Read More

How does the market performance of Hospital Pharmacies compare to Online Portals in 2024?

In 2024, Hospital Pharmacies were valued at 0.606 USD Billion, while Online Portals were valued at 0.406 USD Billion. Read More

What implications do the growth projections for the Hepatitis B Vaccine Market have for future investments?

The projected growth to 3.362 USD Billion by 2035 suggests potential opportunities for investment in vaccine development and distribution. Read More

Hepatitis B Vaccine Market

ID: MRFR/Pharma/27698-HCR

128 Pages

Rahul Gotadki

Last Updated: June 01, 2026

Hepatitis B Vaccine Market Research Report By Type (Monovalent, Combination), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Clinics, Online Portals), By Age Group (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Government Birth-Dose Mandates | |
  2. 3.1.2 Rising HBV Prevalence Awareness | |
  3. 3.1.3 Gavi Co-Financing Expansion | |
  4. 3.1.4 Needle-Free Delivery Innovation | |
  5. 3.1.5 Combination Vaccine Adoption |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Price Erosion from Tendered Procurement | |
  2. 3.2.2 Vaccine Hesitancy Pockets | |
  3. 3.2.3 Cold-Chain Gaps in Remote Regions | |
  4. 3.2.4 Mature-Market Coverage Saturation |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Emerging-Market Birth-Dose Scale-Up | |
  2. 3.3.2 Combination Vaccine Bundling | |
  3. 3.3.3 Needle-Free and Self-Administration Platforms | |
  4. 3.3.4 Localized Manufacturing in Underserved Regions | |
  5. 3.3.5 Data-Driven Coverage Analytics as a Service |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Hepatitis B Vaccine Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Vaccine Type | |
  1. 5.1.1 Single Antigen Vaccine | |
  2. 5.1.2 Combination Vaccine |
2. 5.2 By Age Group | |
  1. 5.2.1 Pediatric | |
  2. 5.2.2 Adult |
3. 5.3 By Packaging Type | |
  1. 5.3.1 Ampoules | |
  2. 5.3.2 Vials | |
  3. 5.3.3 Prefilled Syringes |
4. 5.4 By Distribution Channel | |
  1. 5.4.1 Hospitals | |
  2. 5.4.2 Government Organizations | |
  3. 5.4.3 Non-Government Organizations | |
  4. 5.4.4 Others
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 UK | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of Middle East & Africa
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2026) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 GlaxoSmithKline | |
  2. 7.3.2 Merck & Co. | |
  3. 7.3.3 Serum Institute of India | |
  4. 7.3.4 Sanofi | |
  5. 7.3.5 Dynavax Technologies | |
  6. 7.3.6 Bharat Biotech | |
  7. 7.3.7 Sinovac Biotech | |
  8. 7.3.8 Panacea Biotec | |
  9. 7.3.9 LG Chem | |
  10. 7.3.10 Biological E. Limited
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 Near-Term Outlook (2026–2028) |
2. 8.2 Medium-Term Outlook (2029–2031) |
3. 8.3 Long-Term Outlook (2032–2035)
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Hepatitis B Vaccine Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Hepatitis B Vaccine Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Global Hepatitis B Vaccine Market |
TABLE 4 Restraint Impact Analysis – Global Hepatitis B Vaccine Market |
TABLE 5 Global Hepatitis B Vaccine Market Size, by Vaccine Type, 2021–2035 (USD Billion) |
TABLE 6 Global Hepatitis B Vaccine Market Size, by Age Group, 2021–2035 (USD Billion) |
TABLE 7 Global Hepatitis B Vaccine Market Size, by Packaging Type, 2021–2035 (USD Billion) |
TABLE 8 Global Hepatitis B Vaccine Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 9 Global Hepatitis B Vaccine Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 10 North America Hepatitis B Vaccine Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Europe Hepatitis B Vaccine Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Asia-Pacific Hepatitis B Vaccine Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 South America Hepatitis B Vaccine Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Middle East & Africa Hepatitis B Vaccine Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 Competitive Benchmarking Matrix – Global Hepatitis B Vaccine Market, 2026 |
TABLE 16 Company Profiles – Key Players, Global Hepatitis B Vaccine Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 Report Scope & Methodology Summary |
TABLE 19 Detailed Sources and Citations |
TABLE 20 Regional Market Share Summary, Global Hepatitis B Vaccine Market, 2025
13 LIST OF FIGURES |
FIGURE 1 Global Hepatitis B Vaccine Market – Market Dynamics Overview |
FIGURE 2 Industry Value Chain Analysis – Hepatitis B Vaccine Market |
FIGURE 3 Porter's Five Forces Analysis – Hepatitis B Vaccine Market |
FIGURE 4 Global Hepatitis B Vaccine Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Rate, 2021–2035 |
FIGURE 6 Market Share by Vaccine Type, 2025 |
FIGURE 7 Market Share by Age Group, 2025 |
FIGURE 8 Market Share by Packaging Type, 2025 |
FIGURE 9 Market Share by Distribution Channel, 2025 |
FIGURE 10 Regional Market Share, 2025 |
FIGURE 11 Asia-Pacific Country-Level Growth Comparison |
FIGURE 12 Competitive Landscape – Revenue Share Distribution, 2026

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Vaccine Type	Single Antigen Vaccine, Combination Vaccine	Single Antigen Vaccine	Combination Vaccine
By Age Group	Pediatric, Adult	Pediatric	Adult
By Packaging Type	Ampoules, Vials, Prefilled Syringes	Vials	Prefilled Syringes
By Distribution Channel	Hospitals, Government Organizations, Non-Government Organizations, Others	Government Organizations	Non-Government Organizations

Market Segmentation Overview

By Vaccine Type

Sub-Segment	Key Trend
Single Antigen Vaccine	Monovalent birth dose remains mandatory before combination schedules begin
Combination Vaccine	Pentavalent and hexavalent prequalification accelerates multi-antigen adoption

Single-antigen formulations hold the largest share because the timely birth dose must precede combination scheduling, but combination vaccines drive faster growth as ministries consolidate the HBV immunization schedule into fewer injections.

By Age Group

Sub-Segment	Key Trend
Pediatric	Universal birth-dose and infant-series mandates sustain baseline volume
Adult	Expanded high-risk and universal adult recommendations widen demand

Pediatric demand anchors total volume through near-compulsory neonatal HBV vaccination, while the adult segment grows faster on expanded occupational and universal catch-up guidance.

By Packaging Type

Sub-Segment	Key Trend
Ampoules	Persisting mainly in legacy procurement contracts
Vials	Cost-efficient multi-dose format dominant in high-volume programs
Prefilled Syringes	Fastest growth in dosing accuracy and reduced open-vial wastage

Vials remain dominant in terms of cost efficiency, but prefilled syringes are gaining share as programs prioritize accuracy and wastage reduction.

By Distribution Channel

Sub-Segment	Key Trend
Hospitals	Primary point of birth-dose administration
Government Organizations	Largest channel via national immunization procurement
Non-Government Organizations	Fastest growth through donor-funded outreach
Others	Pharmacy and travel clinic channels are expanding adult access

Government organizations dominate as principal procurers of routine supply, while NGOs grow fastest by extending reach into populations outside formal health systems.

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”